Payment overview · 2025
General Payments
$234.04
8 reported records · 4 companies
Healthcare provider profile · identity verified
Joseph Flowers, MD
Allopathic & Osteopathic Physicians|Family Medicine · WALTERBORO, SC · NPI 1295775708
Verified facts
What the public records show
CMS Open Payments records show Joseph Flowers, MD received $234.04 in general payments during 2025 across 8 reported records.
AstraZeneca Pharmaceuticals LP accounted for 58.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $136.10 | 58.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.90 | 22.2% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $32.20 | 13.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.84 | 5.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $234.04 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $121.98 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $118.56 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $104.44 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $51.90 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $32.20 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.84 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 133 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
133 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 452 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 431 | 146 |
| Losartan Potassium | Losartan Potassium | 383 | 121 |
| Prednisone | Prednisone | 276 | 169 |
| Levothyroxine Sodium | Levothyroxine Sodium | 262 | 72 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 231 | 41 |
| Lorazepam | Lorazepam | 222 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 215 | 70 |
| Metformin Hcl | Metformin Hcl | 207 | 62 |
| Gabapentin | Gabapentin | 205 | 73 |
| Omeprazole | Omeprazole | 201 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 191 | 64 |
| Furosemide | Furosemide | 182 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 161 | 55 |
| Tizanidine Hcl | Tizanidine Hcl | 161 | 72 |
| Azithromycin | Azithromycin | 152 | 117 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 150 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 146 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 146 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 144 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 142 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 57 |
| Eliquis | Apixaban | 133 | 29 |
| Potassium Chloride | Potassium Chloride | 133 | 41 |
| Trazodone Hcl | Trazodone Hcl | 133 | 39 |
| Glimepiride | Glimepiride | 132 | 41 |
| Lisinopril | Lisinopril | 130 | 42 |
| Atenolol | Atenolol | 127 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 48 |
| Meloxicam | Meloxicam | 110 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 34 |
| Allopurinol | Allopurinol | 97 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 96 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 96 | 35 |
| Amoxicillin | Amoxicillin | 93 | 75 |
| Tramadol Hcl | Tramadol Hcl | 88 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 87 | 40 |
| Ozempic | Semaglutide | 86 | 18 |
| Simvastatin | Simvastatin | 86 | 28 |
| Donepezil Hcl | Donepezil Hcl | 83 | 26 |
| Buspirone Hcl | Buspirone Hcl | 82 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 14 |
| Finasteride | Finasteride | 74 | 20 |
| Cefprozil | Cefprozil | 72 | 60 |
| Montelukast Sodium | Montelukast Sodium | 68 | 24 |
| Valsartan | Valsartan | 66 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 63 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 20 |
| Mupirocin | Mupirocin | 58 | 48 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 19 |
| Alprazolam | Alprazolam | 52 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 44 |
| Diazepam | Diazepam | 50 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 50 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 35 |
| Celecoxib | Celecoxib | 48 | 20 |
| Cephalexin | Cephalexin | 48 | 41 |
| Doxepin Hcl | Doxepin Hcl | 48 | 16 |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Chlorthalidone | Chlorthalidone | 45 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 32 |
| Fluconazole | Fluconazole | 44 | 31 |
| Ibuprofen | Ibuprofen | 43 | 14 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 43 | 12 |
| Clonazepam | Clonazepam | 42 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 40 | suppressed |
| Famotidine | Famotidine | 40 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 33 |
| Sucralfate | Sucralfate | 38 | 14 |
| Estradiol | Estradiol | 37 | 11 |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 36 | 11 |
| Pregabalin | Pregabalin | 36 | suppressed |
| Jardiance | Empagliflozin | 35 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 34 | suppressed |
| Irbesartan | Irbesartan | 34 | 11 |
| Memantine Hcl | Memantine Hcl | 34 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 33 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 15 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 33 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Naproxen | Naproxen | 32 | 14 |
| Ondansetron Odt | Ondansetron | 32 | 24 |
| Spironolactone | Spironolactone | 32 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Carvedilol | Carvedilol | 31 | 13 |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Ofloxacin | Ofloxacin | 29 | 23 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | 11 |
| Meclizine Hcl | Meclizine Hcl | 23 | 17 |
| Telmisartan | Telmisartan | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $234.04 · 8 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, ELIQUIS, FARXIGA, Korlym, NURTEC ODT, Ozempic | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error